Imatinib works by specifically binding to the ATP-binding site of the BCR-ABL tyrosine kinase. This binding inhibits the kinase's activity, preventing the phosphorylation of downstream substrates that are crucial for cell proliferation and survival. By blocking this pathway, imatinib effectively induces apoptosis (programmed cell death) in leukemic cells.
